Table 1.
Mean values for age, body mass index, and selected immune parameters in different subgroups included in immune analysisa.
| Parameterb | A | B | C | D | E | F |
|---|---|---|---|---|---|---|
| Age (years) | 39.0 ± 10.1 | 34.7 ± 10.4 | 33.5 ± 7.4 | |||
| BMI | 23.9 ± 2.8 | 23.4 ± 2.4 | 21.7 ± 3.0 | 21.8 ± 3.0 | 21.1 ± 3.5 | 21.0 ± 3.3 |
| Immune parameters | ||||||
| D50-value (BCR) | 1.3 ± 0.8 | 1.3 ± 0.7 | 1.1 ± 0.4 | 1.6 ± 1.7 | 3.0 ± 2.5 | 2.0 ± 2.2 |
| D50-value [T-cell receptor (TCR)] | 5.4 ± 5.4 | 4.6 ± 4.1 | 5.2 ± 5.1 | 6.9 ± 3.9 | 1.8 ± 2.6 | 2.4 ± 2.5 |
| Delta index [B-cell receptor (BCR)] | 0.54 ± 0.23 | 0.69 ± 0.18 | 0.49 ± 0.06 | |||
| Delta index (TCR) | 0.12 ± 0.06 | 0.14 ± 0.07 | 0.13 ± 0.05 | |||
| IgD (%)c | 16.8 ± 2.3 | 14.9 ± 2.3 | 15.1 ± 4.7 | 14.8 ± 2.2 | 15.7 ± 1.3 | 13.5 ± 3.0 |
| IgM (%) | 59.7 ± 7.7 | 56.8 ± 11.6 | 51.1 ± 10.5 | 54.6 ± 9.1 | 59.2 ± 4.1 | 63.6 ± 8.4 |
| IgG (%) | 6.0 ± 1.6 | 5.5 ± 1.3 | 7.0 ± 0.5 | 6.6 ± 0.8 | 5.5 ± 0.8 | 5.1 ± 1.2 |
| IgA (%) | 10.7 ± 6.6 | 15.6 ± 13.5 | 19.9 ± 13.2 | 17.1 ± 3.3 | 13.2 ± 3.3 | 11.4 ± 4.1 |
| IgE (%) | 2.1 ± 1.0 | 1.8 ± 0.7 | 2.5 ± 0.5 | 2.6 ± 0.5 | 1.7 ± 0.5 | 1.9 ± 0.7 |
| Unknown (%) | 4.7 ± 0.9 | 5.3 ± 1.2 | 4.4 ± 0.8 | 4.4 ± 2.4 | 4.9 ± 2.4 | 4.6 ± 1.8 |
| IGHV1 (%)d | 9.5 ± 3.3 | 9.4 ± 2.5 | 7.3 ± 1.7 | 7.0 ± 0.9 | 7.2 ± 2.2 | 8.2 ± 2.3 |
| IGHV2 (%) | 1.0 ± 0.1 | 0.9 ± 0.3 | 1.0 ± 0.2 | 1.0 ± 0.2 | 0.8 ± 0.2 | 1.0 ± 0.1 |
| IGHV3 (%) | 45.7 ± 3.8 | 39.7 ± 5.9 | 49.7 ± 5.3 | 49.5 ± 4.1 | 52.2 ± 9.1 | 53.2 ± 3.8 |
| IGHV4 (%) | 34.4 ± 5.2 | 35.3 ± 4.5 | 32.5 ± 3.6 | 32.3 ± 2.9 | 33.2 ± 7.9 | 30.9 ± 5.3 |
| IGHV5 (%) | 7.4 ± 2.1 | 12.0 ± 5.6 | 7.2 ± 2.4 | 7.9 ± 2.6 | 4.4 ± 1.4 | 4.3 ± 1.1 |
| IGHV6 (%) | 1.9 ± 0.5 | 2.5 ± 0.9 | 2.2 ± 1.1 | 2.1 ± 0.8 | 1.8 ± 0.3 | 1.6 ± 0.3 |
| IGHV7 (%) | 0.2 ± 0.3 | 0.3 ± 0.3 | 0.2 ± 0.2 | 0.2 ± 0.2 | 0.4 ± 0.4 | 0.3 ± 0.4 |
| IGHV3-d (%) | 0.1 ± 0.0 | 0.1 ± 0.1 | 0.2 ± 0.1 | 0.1 ± 0.0 | 0.1 ± 0.0 | 0.1 ± 0.0 |
| IGHV3-9 (%) | 0.6 ± 0.8 | 0.3 ± 0.1 | 0.3 ± 0.1 | 0.2 ± 0.1 | 0.5 ± 0.2 | 0.4 ± 0.1 |
| IGHV3-15 (%) | 1.6 ± 0.3 | 1.3 ± 0.3 | 1.8 ± 0.3 | 1.8 ± 0.5 | 1.9 ± 0.5 | 1.8 ± 0.3 |
| IGHV3-23 (%) | 6.1 ± 1.5 | 5.7 ± 1.6 | 6.9 ± 1.0 | 7.4 ± 1.2 | 8.3 ± 2.2 | 8.1 ± 1.8 |
| IGHV3-33 (%) | 3.3 ± 0.5 | 3.0 ± 0.5 | 3.5 ± 0.4 | 3.3 ± 0.6 | 3.9 ± 1.1 | 4.2 ± 0.9 |
| IGHV3-64 (%) | 6.5 ± 1.8 | 5.7 ± 1.6 | 7.4 ± 1.5 | 7.2 ± 1.5 | 7.4 ± 1.4 | 7.6 ± 0.9 |
| IGHV3-74 (%) | 2.2 ± 0.3 | 1.8 ± 0.3 | 2.3 ± 0.4 | 2.1 ± 0.4 | 2.3 ± 0.8 | 2.4 ± 0.6 |
| IGHV4-34 (%) | 10.5 ± 3.5 | 10.7 ± 3.2 | 10.2 ± 1.6 | 10.0 ± 1.6 | 10.6 ± 2.5 | 10.0 ± 2.4 |
| IGHV4-39 (%) | 7.2 ± 1.8 | 7.1 ± 1.8 | 5.9 ± 1.5 | 5.7 ± 1.6 | 5.0 ± 0.5 | 5.0 ± 0.5 |
| IGHV5-51 (%) | 3.9 ± 1.1 | 5.9 ± 3.0 | 3.8 ± 1.3 | 4.2 ± 1.4 | 2.4 ± 0.8 | 2.7 ± 0.6 |
| IGHV5-a (%) | 3.4 ± 1.0 | 5.5 ± 3.1 | 3.4 ± 1.2 | 3.7 ± 1.2 | 2.0 ± 0.7 | 2.3 ± 0.5 |
| TRBV3-1 (%) | 1.2 ± 1.3 | 1.2 ± 1.5 | 3.2 ± 0.5 | 3.0 ± 0.5 | 0.8 ± 1.5 | 0.8 ± 1.5 |
| TRBV5-8 (%) | 0.2 ± 0.1 | 0.2 ± 0.1 | 0.2 ± 0.1 | 0.2 ± 0.1 | 0.2 ± 0.0 | 0.2 ± 0.0 |
| TRBV7-4 (%) | 0.029 ± 0.008 | 0.033 ± 0.007 | 0.029 ± 0.008 | 0.025 ± 0.006 | 0.047 ± 0.016 | 0.045 ± 0.019 |
| TRBV9 (%) | 1.0 ± 0.2 | 1.1 ± 0.3 | 1.1 ± 0.3 | 1.0 ± 0.3 | 0.8 ± 0.2 | 0.8 ± 0.2 |
| TRBV16 (%) | 0.1 ± 0.0 | 0.1 ± 0.0 | 0.1 ± 0.0 | 0.1 ± 0.0 | 0.1 ± 0.0 | 0.1 ± 0.0 |
aThirty-eight samples from days 0 and 91, respectively, from the study (n = 8, n = 8), control 1 (n = 7, n = 7), and control 2 (n = 4, n = 4) groups were included for immune analysis.
bParameters that are significantly different between subgroups A and B are indicated in bold letters (Wilcoxon signed-rank test). The statistics for the complete data set are presented in Table S9 in Supplementary Material.
cIg frequencies are calculated based on unique Ig–CDR3–C–J combinations.
dV gene usage is calculated based on unique CDR3–V–J combinations.
BMI, body mass index.